Lv1
90 积分 2025-09-03 加入
Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma
4天前
已完结
Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
4天前
求助中
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study
1个月前
已完结
Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas
1个月前
已完结
Advancing understanding of mature T-cell and natural killer-cell lymphomas
1个月前
已完结
Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications
1个月前
已关闭
Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection
1个月前
已完结
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
1个月前
已完结
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
1个月前
已完结
皖公网安备34019202002308
